關於 alnylam ，我們在網路上蒐集到這些相關的討論、資訊與評價

#11. Alnylam 新藥告捷成FDA核准第二支RNAi藥物 - 基因線上

Alnylam Pharmaceutical 所開發的新藥GIVLAARI™（givosiran）獲得美國食品和藥物管理局（FDA）核准，成為第二支獲准的核醣核酸干擾（RNA interference ...

#12. Jobs with Alnylam Pharmaceuticals - BioSpace

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced it has ranked first in Boston Globe's 2021 Top Places to Work in the ...

#13. 我們致力於隱私 - Alnylam Policies

隱私政策和聲明 法律聲明 Cookie政策 Austria Deutsch Datenschutzerklärung und Hinweise › Rechtlich › Erklärung z... Belgium Nederlands Privacybeleid en kennisgevingen › Juridisch › Cookiebelei... Belgium Français Politique de confidentialité et avis › Mentions légales › Politique de...

#14. Where will Novartis spend the $21B from Roche stake sale ...

Alnylam pressed on with the Nobel prize-winning science and successfully introduced Onpattro in 2018 as the first FDA-approved RNAi therapeutic.

#15. Alnylam Pharmaceuticals (ALNY) - Forbes

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It ...

#16. Alnylam Pharmaceuticals, Inc. - MassBio

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a revolution in biology, representing a ...

#17. Alnylam Pharmaceuticals - YouTube

Alnylam has been working since 2002 to pioneer RNAi-based medicines called RNAi therapeutics and bring them to patients as an innovative new class of ...

#18. ALNY.O - Alnylam Pharmaceuticals, Inc. Profile | Reuters

Alnylam Reports Positive Topline Results From Phase 3 Study Of Vutrisiran In Patients With hATTR Amyloidosis With Polyneuropathy.

#19. Alnylam Pharmaceuticals - Crunchbase Company Profile ...

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.

#20. ALNYLAM PHARMACEUTICALS INC - SEC.gov

Alnylam is a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on a recently discovered biological pathway known as RNA ...

#21. ALNY | Alnylam Pharmaceuticals Inc. Stock Price & News - WSJ

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.

#22. Alnylam Pharmaceuticals | Cambridge, United States |

Find 115 researchers and browse 1 departments, publications, full-texts, contact details and general information related to Alnylam Pharmaceuticals ...

#23. Alnylam Act Hereditary ATTR Amyloidosis - Invitae

Alnylam -sponsored genetic testing for individuals who may carry a gene mutation known to be associated with hereditary ATTR (hATTR) amyloidosis.

#24. Alnylam Announces U.S. Food and Drug Administration ...

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential ...

#25. ALNY: Alnylam Pharmaceuticals Inc Stock Price Quote

Stock analysis for Alnylam Pharmaceuticals Inc (ALNY:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company ...

#26. Alnylam Assist® Patient Support

Learn how Alnylam Assist® can help patients get started on treatment with ONPATTRO® (patisiran), GIVLAARI® (givosiran), or OXLUMO™ (lumasiran).

#27. Alnylam UK Ltd - Great Place to Work

Alnylam UK Ltd - Alnylam is leading the translation of RNA interference (RNAi) - an approach also known as 'gene silencing' - into a whole new class of ...

#28. Alnylam is getting a rare kind of leader - The Boston Globe

Yvonne Greenstreet will become the CEO of Cambridge's Alnylam ... chief executive of Alnylam Pharmaceuticals, one of Massachusetts' biggest ...

#29. Job Search

Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.

#30. Alnylam Pharmaceuticals Inc. - Instagram

Alnylam Pharmaceuticals Inc. The world's leading RNAi therapeutics company, pioneering this new class of medicines since 2002. Links related to our recent ...

#31. Alnylam Pharmaceuticals Inc ALNY:NASDAQ - CNBC

Get Alnylam Pharmaceuticals Inc (ALNY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

#32. Alnylam - British Society of Echocardiography

Alnylam is leading the translation of RNA interference (RNAi) into a whole class of innovative medicines with the potential to help patients who have ...

#33. Alnylam Pharmaceuticals, Inc. Common Stock (ALNY) - Nasdaq

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for ...

#34. Alnylam | Science | AAAS

Alnylam is leading the translation of RNA interference (RNAi) into an innovative new class of medicines which we believe have the potential to transform the ...

#35. Alnylam launches era of RNAi drugs | Nature Biotechnology

But Onpattro could prove a very lucrative drug for Alnylam, the clear leader in the RNAi therapeutics field. Transthyretin amyloidosis “is an ...

#36. Alnylam Pharmaceuticals - Atlas Venture

Alnylam (NASDAQ: ALNY) is developing a novel class of drugs based on RNA interference, and is pursuing a range of targets in genetic medicine, ...

#37. Alnylam Pharmaceuticals Grants InterfeRx(TM) Intellectual ...

Alnylam Pharmaceuticals Grants InterfeRx(TM) Intellectual Property License to Sylentis for Development and Commercialization of RNAi Therapeutics.

#38. Alnylam Reviews | Glassdoor

120 Alnylam reviews. A free inside look at company reviews and salaries posted anonymously by employees.

#39. Alnylam scraps COVID-19 antiviral citing effective vaccines ...

Alnylam Pharmaceuticals and Vir Biotechnology are ditching their COVID-19 antiviral as the Delta variant picks up steam throughout the world ...

#40. All medicines for Alnylam UK Ltd - (emc)

[email protected]. WWW. https://www.alnylam.com/. Medical Information Direct Line. 08001412569 (+44 (0) 1628878592). 3 results found.

#41. Alnylam Pharmaceuticals Inc (ALNY) Quote - XNAS

Investors reacted negatively as Alnylam's third-quarter results missed FactSet consensus estimates. During the quarter, Alnylam lost $1.72 ...

#42. John Maraganore on what comes next for Alnylam and his ...

John Maraganore, the longtime CEO of Alnylam Pharmaceuticals, is stepping down after almost 20 years at the company.

#43. Alnylam - Vivli

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of ...

#44. Alnylam Pharmaceuticals, Inc. Company Information - Drugs ...

Alnylam Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 2 drugs in the U.S..

#45. Why Alnylam Pharmaceuticals Is Crashing Today - The Motley ...

Shares of Alnylam Pharmaceuticals ( ALNY 1.62% ) were tanking on Thursday after the company reported its earnings results for the third ...

#46. Alnylam Pharmaceuticals and GENESIS Pharma partner to ...

The agreement between Alnylam and GENESIS Pharma covers patisiran, approved in the EU in August 2018 for the treatment of hATTR amyloidosis in ...

#47. The Nonclinical Disposition and PK/PD Properties of GalNAc ...

Affiliations. 1 Drug Metabolism and Pharmacokinetics, Alnylam Pharmaceuticals Inc., United States. 2 Clinical Pharmacology, Alnylam ...

#48. Alnylam shares take a hit amid sluggish sales of first drug

Shares of Alnylam Pharmaceuticals fell Wednesday after the Cambridge biotech reported a slow uptake of its first FDA-approved drug, ...

#49. Advancing Alnylam's Five-Year Plan: Tolga Tanguler

Alnylam (Cambridge, MA) is a leading RNAi therapeutics company whose pioneering work delivered the world's first and only approved RNAi ...

#50. Alnylam joins GSK in donating intellectual property to patent ...

GlaxoSmithKline (GSK) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that Alnylam will contribute more than 1500 issued or ...

#51. Alnylam's Manufacturing Facility, Norton, Massachusetts

Alnylam Pharmaceuticals is a global leader in the development of novel therapeutics based on RNA interference and translation of RNAi as a new class of ...

#52. Search for alnylam - EU Clinical Trials Register

Sponsor Name:Alnylam Pharmaceuticals, Inc. Full Title: An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients ...

#53. Alnylam Inaugurates New Biotech Facility in the Netherlands

Alnylam Pharmaceuticals announced the opening of its new office in the Zuidas district of Amsterdam and the Netherlands' life sciences and ...

#54. Alnylam Pharmaceuticals: Most Innovative Company

Alnylam Pharmaceuticals. Alnylam became the first company to bring an RNA interference (RNAi) treatment to market, winning FDA approval for its drug Onpattro ...

#55. In first, FDA approves RNA interference drug from Alnylam

Alnylam's drug, called Onpattro, stems from Nobel Prize-winning research into the therapeutic applications of a cellular process known as RNA ...

#56. Regeneron will pay Alnylam $800 million to get RNAi into the ...

For the new realms of the eye and central nervous system, it's not yet clear how Alnylam will deliver RNAi drugs, though both organs will likely ...

#57. Sanofi and Alnylam present positive complete results from ...

Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) ...

#58. Alnylam Pharmaceuticals Employee Reviews - Indeed

Reviews from Alnylam Pharmaceuticals employees about Alnylam Pharmaceuticals culture, salaries, benefits, work-life balance, management, job security, ...

#59. Alnylam Extends RNAi Alliance with UBC and AlCana ...

Alnylam Pharmaceuticals will extend its RNAi therapeutics research collaboration with AlCana Technologies and The University of British ...

#60. Alnylam Pharmaceuticals (ALNY) - Market capitalization

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically ...

#61. Alnylam and Arrowhead Form Collaboration and Licensing ...

– Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic Toward Hepatitis B Virus (HBV) – – Alnylam Gains Access to Arrowhead's ...

#62. Alnylam Pharmaceuticals Inc Share Price Com Stk USD0.01

The latest Alnylam Pharmaceuticals Inc Com Stk USD0.01 share price. View recent trades and share price information for Alnylam Pharmaceuticals Inc Com Stk ...

#63. Press Releases | Investor Relations - Alnylam ...

Summary ToggleAlnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, ...

#64. Blackstone and Alnylam Announce Collaboration to Advance ...

Today, Blackstone announced a new collaboration with Alnylam, a world-leading biotech company and a pioneer in the field of RNA interference ...

#65. Alnylam：开创全球RNAi药物的未来（第一部分）

主要公司：Alnylam Pharmaceuticals (NASDAQ: ALNY) ... 公司主页：http://www.alnylam.com ... 一、Alnylam在RNAi治疗药物上的研发平台及进展.

#66. Press Release Details - Investors - Ironwood Pharmaceuticals

Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam's Givosiran in Acute ...

#67. Dicerna can't catch up with Alnylam | Evaluate

Phyox2 data back Dicerna's nedosiran in just one type of primary hyperoxaluria, where Alnylam already has an 18-month head start.

#68. HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients ...

Alnylam Pharmaceuticals. Information provided by (Responsible Party):. Alnylam Pharmaceuticals ... Study Director: Medical Director, Alnylam Pharmaceuticals ...

#69. Alnylam launches digital tool for ATTR amyloidosis patients -

Alnylam launches a digital health app for people with rare disease hATTR amyloidosis that aims to help them track symptoms and communicate ...

#70. Hochschulmedizin Zurich and Alnylam Host Innovative ...

Hochschulmedizin Zurich and Alnylam Host Innovative Medicine Lecture on the Discovery and Clinical Applications of RNA interference (RNAi).

#71. Alnylam Pharmaceuticals Inc. Stock Quote (US - ALNY

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.

#72. Alnylam Wheels, Deals, and Gets $700M Investment From ...

A few years ago, Genzyme struck a deal with Alnylam Pharmaceuticals (NASDAQ: ]) to grab some rights to an RNA interference drug program for ...

#73. Alnylam becomes a partner in the Medicines Manufacturing…

CPI welcomes Alnylam as the latest partner in the Medicines Manufacturing Innovation Centre's third Grand Challenge project.

#74. Alnylam settles 'inherently unpredictable' patent litigation over ...

Alnylam settled its patent litigation with Silence Therapeutics, after an ongoing litigation regarding patent infringement of Silence's RNAi ...

#75. Alnylam Pharmaceuticals Inc, ALNY:NSQ summary - FT.com

Latest Alnylam Pharmaceuticals Inc (ALNY:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and ...

#76. Nanotechnology Intellectual Property Rights: Research, ...

Tekmira did not grant Alnylam ownership of its delivery technology; the delivery technology remained Tekmira's property before, during, and after Tekmira's ...

#77. Alnylam FDA submission aims to expand biotech's franchise ...

Alnylam Pharmaceuticals has filed for FDA approval of vutrisiran, which could become the biotech's fourth drug that works by RNA ...

#78. Regeneron and Alnylam Announce Broad Collaboration to ...

Under the terms of the alliance, Alnylam will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases.

#79. ALNY | Alnylam Pharmaceuticals Inc股市 - Investing.com 香港

獲得Alnylam Pharmaceuticals Inc股票的詳盡資料，包括價格、圖表、技術分析、歷史數據及Alnylam Pharma報告等。

#80. Dicerna與Alnylam和解！股價狂飆進軍RNAi療法市場 - Genet ...

Dicerna終於與Alnylam和解纏鬥多年的專利官司，上週五宣布消息後股價衝出30%，一吐鬱積許久的悶氣。Dicerna付了對手Alnylam 200萬美元授權金、四年 ...

#81. Cystic Fibrosis Foundation Therapeutics and Alnylam Initiate ...

Alnylam will apply RNAi technology toward the discovery of short interfering RNAs (siRNAs), the molecules that induce RNA interference, ...

#82. Alnylam艾拉倫藥廠在台設立據點首款RNAi藥物為罕病治療現曙光

【本報記者鐘翠珠台北報導】美國生物製藥公司Alnylam艾拉倫藥廠今(21/29)日舉辦記者會，處長張東凱說明在台取得藥物許可證，正式宣布在台設立據點； ...

#83. Alnylam Pharmaceuticals, UK - Hereva Consultants Inc.

Expansion into the UK and EU is one of the goals of Alnylam's “2020 Initiative.” To that end, in 2016 Hereva supported Alnylam in selecting a site in the ...

#84. Alnylam Pharmaceuticals partners with Sharp on packaging ...

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), the leading RNA interference (RNAi) therapeutics company, and Sharp, part of UDG Healthcare, today announced an ...

#85. Maraganore leaves Alnylam with an eye for science, a heart ...

An exit interview with the outgoing CEO of Alnylam. By C. Simone Fishburn, Editor in Chief. December 1, 2021 10:16 PM PST. Get Unlimited Access.

#86. Alnylam - Fondazione Sodalitas

Alnylam è un'azienda biofarmaceutica fondata nel 2002 con l'ambizione di trasformare una rivoluzionaria scoperta - insignita del Premio Nobel per la ...

#87. 生物制藥公司：阿裡拉姆制藥Alnylam Pharmaceuticals(ALNY)

Alnylam Pharmaceuticals於2002由Phillip Sharp、Paul Schimmel、Dave Bartel、Thomas Tuschl 和 Phillip Zamore創立，是一家生物制藥公司.

#88. Alnylam Rockets On Strong Rare-Disease Drug Data; Ionis ...

Alnylam shares soared by nearly a third premarket on drug trial data. ... Alnylam Pharmaceuticals (ALNY) shares catapulted upward by more ...

#89. Norton pharmaceutical business up for state award - The Sun ...

Alnylam Pharmaceuticals, located in the The Commerce Center, the town's business park, is in the running for the MassEcon's 18th annual Team ...

#90. 5年內成為全球5大生物技術公司之一！Alnylam展示RNAi治療 ...

在RNAi新藥開發領域，Alnylam Pharmaceuticals是備受關注的「明星公司」。2018年，該公司研發的Onpattro（patisiran）成為首款獲得FDA批准的RNAi療法 ...

#91. Novartis Has a Big Pile of Cash and Investors Are Demanding ...

Buying a biotech company is one option, with Alnylam Pharmaceuticals Inc. -- a company with a market value in excess of $20 billion -- a prime ...

#92. Alnylam Pharmaceuticals Provides Perspective on Positive ...

“The ORION-11 results represent a landmark event for Alnylam and RNAi therapeutics. With over 1,600 patients enrolled, ORION-11 is the largest ...

#93. 阿里拉姆制药(艾拉伦制药)Alnylam Pharmaceuticals(ALNY)

阿里拉姆制药公司Alnylam Pharmaceuticals, Inc.(NASDAQ:ALNY)成立于2002年，总部位于美国马萨诸塞州剑桥市，全职雇员256人，是一家RNA干扰创新疗法的 ...

#94. Alnylam solicita registro do medicamento Onpattro (patisirana ...

A Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), líder mundial em tratamentos de RNAi, anunciou hoje que a autorização de comercialização de ...

#95. Is Alnylam Pharmaceuticals, Inc. (ALNY) a Bad Choice in ...

The 42 rating InvestorsObserver gives to Alnylam Pharmaceuticals, Inc. (ALNY) stock puts it near the middle of the.

#96. Alnylam Ranks #1 in Boston Globe's Top Places to Work List ...

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential ...

#97. Login | Okta

Please enter your organization's address. We'll send you to your own login page, where you can access your account directly. Your Site Address .okta.com. Submit.